Frequent FGFR3 mutations in urothelial papilloma

Journal of Pathology

Volumn 198, Issue 2, 2002, Pages 245-251

  Van Rhijn, Bas W G ^a,b   Montironi, Rodolfo ^c   Zwarthoff, Ellen C ^a   Jöbsis, Adriaan C ^d   Van Der Kwast, Theo H ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

Bladder; Borderline malignancy; Brenner tumour; Cancer; FGFR3; Ovary; Papilloma; Precursor; Urothelial cell carcinoma

Indexed keywords

DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ADULT; AGED; ARTICLE; BLADDER PAPILLOMA; BRENNER TUMOR; CANCER CLASSIFICATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENETIC DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; POINT MUTATION; PRIORITY JOURNAL; TUMOR RECURRENCE; UROGENITAL TRACT TUMOR;

ADULT; AGED; ANALYSIS OF VARIANCE; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SQUAMOUS CELL; POINT MUTATION; PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR; URINARY BLADDER NEOPLASMS;

EID: 0036772919     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1202     Document Type: Article

References (34)

1. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. International Classification of Tumours, No. 10. World Health Organization: Geneva, 1973; 21-31.
2. Epstein JI, Amin MB, Reuter VR, Mostofi FK. Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998; 22: 1435-1448.
3. Bostwick DG, Ramnani D, Cheng L. Diagnosis and grading of bladder cancer and associated lesions. Urol Clin North Am 1999; 26: 493-507.
4. Cheng L, Darson M, Cheville JC, et al. Urothelial papilloma of the bladder. Clinical and biologic implications. Cancer 1999; 86: 2098-2101.
5. Eble JN, Young RH. Benign and low-grade papillary lesions of the urinary bladder: a review of the papilloma-papillary carcinoma controversy, and a report of five typical papillomas. Semin Diagn Pathol 1989; 6: 351-371.
6. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163: 73-78.
7. Johnson DE, Williams LT. Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 1993; 60: 1-41.
8. Perez-Castro AV, Wilson J, Altherr MR. Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) and comparative sequence analysis with the mouse Fgfr3 gene. Genomics 1997; 41: 10-16.
9. Vajo Z, Francomano CA, Wilkin DJ. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr Rev 2000; 21: 23-39.
10. Bellus GA, Spector EB, Speiser PW, et al. Distinct missense mutations of the FGFR3 Lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. Am J Hum Genet 2000; 67: 1411-1421.
11. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genet 1997; 16: 260-264.
12. Capellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genet 1999; 23: 18-20.
13. Fracchiolla NS, Luminari S, Baldini L, Lombardi L, Maiolo AT, Neri A. FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma. Blood 1998; 92: 2987-2989.
14. Wu R, Connolly D, Ngelangel C, Bosch FX, Muñoz N, Cho KR. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix. Oncogene 2000; 19: 5543-5546.
15. Sibley K, Stern P, Knowles MA. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene 2001; 20: 4416-4418.
16. Karoui M, Hofmann-Radvanyi H, Zimmermann U, et al. No evidence of somatic FGFR3 mutation in various types of carcinoma. Oncogene 2001; 20: 5059-5061.
17. Van Rhijn BWG, Lurkin I, Radvanyi F, Kirkels WJ, Van der Kwast ThH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001; 61: 1265-1268.
18. Billerey C, Chopin D, Aubriot-Lorton M-H, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumours. Am J Pathol 2001; 158: 1955-1959.
19. Sobin LH, Fleming ID. TNM Classification of Malignant Tumours, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80: 1803-1804.
20. Sibley K, Cuthbert-Heavens D, Knowles MA. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 2001; 20: 686-691.
21. Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications. Cancer 1999; 86: 2102-2108.
22. Desai S, Lim SD, Jimenez RE, et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol 2000; 13: 1315-1323.
23. Cina SJ, Lancaster-Weiss KJ, Lecksell K, Epstein JI. Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia. Arch Pathol Lab Med 2001; 125: 646-651.
24. Helpap B, Kollermann J. Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions: a contribution to the new WHO classification of the urothelial tumours of the urinary bladder. Hum Pathol 2000; 31: 745-750.
25. Chow NH, Cairns P, Eisenberger CF, et al. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 2000; 89: 514-518.
26. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res 1994; 54: 531-538.
27. Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet 1993; 342: 469-471.
28. Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumours: relationship to grade, immunohistochemical expression of tumour markers, mitotic frequency and DNA ploidy. J Urol 2001; 165: 1124-1128.
29. Alsheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumours. World/Health Organization/International Society of Urologic Pathology. Mod Pathol 2001; 14: 267-272.
30. Ooms EC, Anderson WA, Alons CL, Boon ME, Veldhuizen RW. Analysis of the performance of pathologists in the grading of bladder tumours. Hum Pathol 1983; 14: 140-143.
31. Harnden P, Southgate J. Revised classification of urothelial neoplasms. Am J Surg Pathol 2000; 24: 160-162.
32. Harnden P, Mahmood N, Southgate J. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet 1999; 353: 974-977.
33. Ogawa K, Johansson SL, Cohen SM. Immunohistochemical analysis of uroplakins, urothelial specific proteins, in ovarian Brenner tumours, normal tissues, and benign and neoplastic lesions of the female genital tract. Am J Pathol 1999; 155: 1047-1050.
34. Riedel I, Czemobilsky B, Lifschitz-Mercer B, et al. Brenner tumours but not transitional cell carcinomas of the ovary show urothelial differentiation: immunohistochemical staining of urothelial markers, including cytokeratins and uroplakins. Virchows Arch 2001; 438: 181-191.